Home › Trial NCT07615413
Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
- Trial IDNCT07615413
- StatusNot Yet Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorJiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrollment636
- Start date2026-06-30
- ConditionsKRAS G12C Mutation Advanced Solid Tumor
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.